questionsmedicales.fr
Disciplines des sciences naturelles
Science
Recherche
Recherche biomédicale
Expérimentation humaine
Expérimentation humaine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Essais cliniques
Sécurité des patients
Tests diagnostiques
Imagerie médicale
Effets indésirables
Surveillance des patients
Groupes témoins
Essais contrôlés
Critères d'inclusion
Sélection des participants
Symptômes
5
Symptômes
Réactions indésirables
Effets indésirables
Signalement des événements
Variabilité des symptômes
Groupes de traitement
Évaluation des symptômes
Questionnaires
Prévention
5
Prévention des effets indésirables
Surveillance des participants
Consentement éclairé
Évaluation des risques
Information des participants
Consentement éclairé
Recommandations pour les participants
Instructions d'étude
Évaluation de la prévention
Analyses de données
Traitements
5
Médicaments expérimentaux
Thérapies
Administration de médicaments
Voies d'administration
Traitement de contrôle
Comparaison des traitements
Efficacité des traitements
Mesures cliniques
Médecine personnalisée
Profilage génétique
Complications
5
Complications
Réactions allergiques
Gestion des complications
Soins médicaux
Documentation des complications
Rapports d'étude
Prévention des complications
Suivi des participants
Conséquences des complications
Arrêt d'essai
Facteurs de risque
5
Facteurs de risque
Antécédents médicaux
Évaluation des risques
Questionnaires médicaux
Variabilité des risques
Traitements
Minimisation des risques
Sélection des participants
Communication des risques
Consentement éclairé
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Expérimentation humaine : Questions médicales les plus fréquentes",
"headline": "Expérimentation humaine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Expérimentation humaine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Expérimentation humaine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Recherche biomédicale",
"url": "https://questionsmedicales.fr/mesh/D035843",
"about": {
"@type": "MedicalCondition",
"name": "Recherche biomédicale",
"code": {
"@type": "MedicalCode",
"code": "D035843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Expérimentation sur soi-même",
"alternateName": "Autoexperimentation",
"url": "https://questionsmedicales.fr/mesh/D032762",
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation sur soi-même",
"code": {
"@type": "MedicalCode",
"code": "D032762",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145.365.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Expérimentation humaine non thérapeutique",
"alternateName": "Nontherapeutic Human Experimentation",
"url": "https://questionsmedicales.fr/mesh/D033281",
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation humaine non thérapeutique",
"code": {
"@type": "MedicalCode",
"code": "D033281",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145.365.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Expérimentation thérapeutique humaine",
"alternateName": "Therapeutic Human Experimentation",
"url": "https://questionsmedicales.fr/mesh/D036302",
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation thérapeutique humaine",
"code": {
"@type": "MedicalCode",
"code": "D036302",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145.365.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation humaine",
"alternateName": "Human Experimentation",
"code": {
"@type": "MedicalCode",
"code": "D006805",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Peter Pickkers",
"url": "https://questionsmedicales.fr/author/Peter%20Pickkers",
"affiliation": {
"@type": "Organization",
"name": "Dept. of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: peter.pickkers@radboudumc.nl."
}
},
{
"@type": "Person",
"name": "Paul R Chapman",
"url": "https://questionsmedicales.fr/author/Paul%20R%20Chapman",
"affiliation": {
"@type": "Organization",
"name": "Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia."
}
},
{
"@type": "Person",
"name": "Paul Giacomin",
"url": "https://questionsmedicales.fr/author/Paul%20Giacomin",
"affiliation": {
"@type": "Organization",
"name": "Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia."
}
},
{
"@type": "Person",
"name": "Alex Loukas",
"url": "https://questionsmedicales.fr/author/Alex%20Loukas",
"affiliation": {
"@type": "Organization",
"name": "Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia."
}
},
{
"@type": "Person",
"name": "James S McCarthy",
"url": "https://questionsmedicales.fr/author/James%20S%20McCarthy",
"affiliation": {
"@type": "Organization",
"name": "Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The socioeconomic distribution of life expectancy and healthy life expectancy in Chile.",
"datePublished": "2023-08-22",
"url": "https://questionsmedicales.fr/article/37608366",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12939-023-01972-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Life expectancy and healthy life expectancy of patients with advanced schistosomiasis in Hunan Province, China.",
"datePublished": "2023-01-28",
"url": "https://questionsmedicales.fr/article/36709305",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40249-023-01053-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "The underwhelming German life expectancy.",
"datePublished": "2023-04-25",
"url": "https://questionsmedicales.fr/article/37185793",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10654-023-00995-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Life expectancy by ethnic origin in Chile.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37397745",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2023.1147542"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Ecology of Economic Distress and Life Expectancy.",
"datePublished": "2024-07-26",
"url": "https://questionsmedicales.fr/article/39132383",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/ijph.2024.1607295"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Disciplines des sciences naturelles",
"item": "https://questionsmedicales.fr/mesh/D010811"
},
{
"@type": "ListItem",
"position": 3,
"name": "Science",
"item": "https://questionsmedicales.fr/mesh/D012586"
},
{
"@type": "ListItem",
"position": 4,
"name": "Recherche",
"item": "https://questionsmedicales.fr/mesh/D012106"
},
{
"@type": "ListItem",
"position": 5,
"name": "Recherche biomédicale",
"item": "https://questionsmedicales.fr/mesh/D035843"
},
{
"@type": "ListItem",
"position": 6,
"name": "Expérimentation humaine",
"item": "https://questionsmedicales.fr/mesh/D006805"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Expérimentation humaine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Expérimentation humaine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Expérimentation humaine",
"description": "Comment évaluer la sécurité d'un essai clinique ?\nQuels tests sont utilisés pour les essais cliniques ?\nComment identifier les effets secondaires ?\nQu'est-ce qu'un groupe témoin ?\nComment sont définis les critères d'inclusion ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Life+Expectancy#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Expérimentation humaine",
"description": "Quels symptômes surveiller lors d'un essai ?\nComment signaler un effet indésirable ?\nLes symptômes peuvent-ils varier selon les groupes ?\nQuels sont les symptômes courants des essais ?\nComment évaluer l'impact des symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Life+Expectancy#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Expérimentation humaine",
"description": "Comment prévenir les effets indésirables ?\nQuelles sont les mesures de sécurité en essais ?\nComment informer les participants des risques ?\nQuelles sont les recommandations pour les participants ?\nComment évaluer la prévention dans les essais ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Life+Expectancy#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Expérimentation humaine",
"description": "Quels types de traitements sont testés ?\nComment sont administrés les traitements ?\nQu'est-ce qu'un traitement de contrôle ?\nComment évaluer l'efficacité d'un traitement ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Life+Expectancy#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Expérimentation humaine",
"description": "Quelles complications peuvent survenir ?\nComment gérer les complications pendant un essai ?\nLes complications sont-elles documentées ?\nComment prévenir les complications graves ?\nQuelles sont les conséquences des complications ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Life+Expectancy#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Expérimentation humaine",
"description": "Quels sont les facteurs de risque pour les essais ?\nComment évaluer les facteurs de risque ?\nLes facteurs de risque varient-ils selon les traitements ?\nComment minimiser les facteurs de risque ?\nLes facteurs de risque sont-ils communiqués aux participants ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Life+Expectancy#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la sécurité d'un essai clinique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La sécurité est évaluée par des comités d'éthique et des protocoles rigoureux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les essais cliniques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques, biologiques et d'imagerie sont utilisés pour évaluer les effets."
}
},
{
"@type": "Question",
"name": "Comment identifier les effets secondaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont identifiés par la surveillance des participants et des rapports."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un groupe témoin ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un groupe témoin est un groupe de participants qui ne reçoit pas le traitement testé."
}
},
{
"@type": "Question",
"name": "Comment sont définis les critères d'inclusion ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères d'inclusion sont définis par des caractéristiques spécifiques des participants."
}
},
{
"@type": "Question",
"name": "Quels symptômes surveiller lors d'un essai ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes à surveiller incluent la douleur, la fatigue et les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment signaler un effet indésirable ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les participants doivent signaler tout effet indésirable à l'équipe de recherche immédiatement."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier selon les groupes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon le groupe de traitement et les caractéristiques des participants."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des essais ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes courants incluent des nausées, des maux de tête et des réactions cutanées."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact des symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact est évalué par des questionnaires et des échelles de mesure standardisées."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut une sélection rigoureuse des participants et une surveillance étroite."
}
},
{
"@type": "Question",
"name": "Quelles sont les mesures de sécurité en essais ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mesures incluent des consentements éclairés, des évaluations de risques et des protocoles stricts."
}
},
{
"@type": "Question",
"name": "Comment informer les participants des risques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les participants reçoivent des informations détaillées lors du processus de consentement éclairé."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les participants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les participants doivent suivre les instructions de l'étude et signaler tout problème de santé."
}
},
{
"@type": "Question",
"name": "Comment évaluer la prévention dans les essais ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des études de suivi et des analyses des données de sécurité."
}
},
{
"@type": "Question",
"name": "Quels types de traitements sont testés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des médicaments, des thérapies physiques ou des interventions chirurgicales."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent être administrés par voie orale, intraveineuse ou topique selon l'étude."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un traitement de contrôle ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement de contrôle est un traitement standard utilisé pour comparer l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des mesures cliniques et des résultats rapportés par les patients."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains essais cliniques testent des traitements personnalisés basés sur le profil génétique."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des infections, des réactions allergiques ou des effets graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications pendant un essai ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont gérées par des protocoles d'urgence et des soins médicaux appropriés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles documentées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, toutes les complications doivent être documentées dans les rapports d'étude."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une évaluation rigoureuse des participants et un suivi constant."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences peuvent inclure l'arrêt de l'essai, des soins médicaux supplémentaires ou des poursuites."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les essais ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent l'âge, les antécédents médicaux et les comorbidités."
}
},
{
"@type": "Question",
"name": "Comment évaluer les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque sont évalués par des questionnaires et des examens médicaux."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque varient-ils selon les traitements ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les facteurs de risque peuvent varier selon le type de traitement et la population étudiée."
}
},
{
"@type": "Question",
"name": "Comment minimiser les facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "La minimisation passe par une sélection rigoureuse des participants et des protocoles adaptés."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque sont-ils communiqués aux participants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les participants sont informés des facteurs de risque lors du consentement éclairé."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 31/03/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Dept. of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: peter.pickkers@radboudumc.nl.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia.
Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia.
Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico,", Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Precision and Translational Medicine, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. ktodd@uga.edu.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. ratripp@uga.edu.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, I-34149 Trieste, Italy.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Life Sciences, Cattinara University Hospital, University of Trieste, Strada di Fiume 447, I-34149 Trieste, Italy.
Publications dans "Expérimentation humaine" :
Life expectancy (LE) has usually been used as a metric to monitor population health. In the last few years, metrics such as Quality-Adjusted-Life-Expectancy (QALE) and Health-Adjusted-Life- Expectancy...
Based on life tables constructed using Chiang II´s method, we estimated the LE of the population in Chile by age strata. Probabilities of dying were estimated from mortality data obtained from nationa...
LE at birth for Chile was estimated in 80.4 years, which is consistent with demographic national data. QALE and HALE at birth were 69.8 and 62.4 respectively. Men are expected to live 6.1% less than w...
The distribution of LE, QALE and HALEs in Chile shows a clear gradient favouring better-off populations that decreases over people´s lives. Differences in LE favouring women contrast with differences ...
Few studies have investigated the change in life expectancy (LE) and the healthy lifespan among patients with advanced schistosomiasis. This study was to evaluate the LE and healthy life expectancy (H...
We utilized data from a dynamic advanced schistosomiasis cohort (10,362 patients) for the period from January 2008 to December 2019 in Hunan Province, China, to calculate the LEs of patients, and made...
The estimated LE for advanced schistosomiasis patients aged 15-19 was 49.51 years (48.86 years for males and 51.07 years for females), which was 20.14 years lower compared with general population (69....
The LE of advanced schistosomiasis patients was still much lower compared with general population. Strengthened prevention strategies and targeted treatments are needed to reduce morbidity and mortali...
This article contributes to the discussion on the determinants of diverging life expectancy in high-income countries, with a focus on Germany. To date, much of this discourse has centered around the s...
Ethnic and racial differences in life expectancy have been well established in different societies. However, even though an important part of the population of Latin America is Indigenous, there is li...
Determine if there are ethnic differences in life expectancy at birth and at 60 years in Chile, and if the Mapuche (largest Indigenous ethnic group) have similar life expectancy to other Indigenous pe...
Life tables for the Mapuche and other Indigenous groups and non-Indigenous people were built using the 2017 census. Specifically, we used the questions of the number of live children born and the numb...
Indigenous Chileans have seven years lower life expectancy at birth than the non-Indigenous population (76.2 vs. 83.2 years). The differential at age 60 is 6 years (20.3 vs. 26.4 years). We also found...
Our results ratify the existence of marked ethnic-racial inequality in the extension of life in Chile and demonstrate a greater disadvantage in terms of survival of the Mapuche compared to other Indig...
To determine whether life expectancy (LE) changes between 2000 and 2019 were associated with race, rural status, local economic prosperity, and changes in local economic prosperity, at the county leve...
Between 12/1/22 and 2/28/23, we conducted a retrospective analysis of 2000 and 2019 data from 3,123 United States counties. For Total, White, and Black populations, we compared LE changes for counties...
In both years, overall, across the rural-urban continuum, and for all studied populations, LE decreased with each progression from the most to least prosperous quintile (all...
At the county level, race, rurality, and local economic distress were all associated with LE; improvements in local economic conditions were associated with accelerated LE. Policymakers should appreci...
Exploring global differences in life expectancy can facilitate the development of strategies to narrow regional disparities. However, few researchers have systematically examined patterns in the evolu...
National projections of life expectancy are made periodically by statistical offices or actuarial societies in Europe and are widely used, amongst others for reforms of pension systems. However, these...
We used a three-layer Li and Lee model with data from neighboring countries to complement Dutch time series....
Our results point at further increases of life expectancy between age 35 and 85 and of remaining life expectancy at age 35 and age 65, for all education groups in the Netherlands. The projected increa...
The educational inequalities in life expectancy are expected to persist or slightly increase for both men and women. The persistence and possible increase of inequalities in life expectancy between th...
Life expectancy is a key measure of overall population health. Life expectancy estimates for youth with HIV in the US are needed in the current HIV care and treatment context to guide health policies ...
To compare life expectancy between 18-year-old youth with perinatally acquired HIV (PHIV), youth with nonperinatally acquired HIV (NPHIV), and youth without HIV....
Using a US-focused adolescent-specific Monte Carlo state-transition HIV model, we simulated individuals from age 18 years until death. We estimated probabilities of HIV treatment and care engagement, ...
HIV status by timing of acquisition....
Life expectancy loss for youth with PHIV and youth with NPHIV: difference between mean projected life expectancy under current and ideal HIV care scenarios compared with youth without HIV. Uncertainty...
Compared with youth without HIV (life expectancy: male, 76.3 years; female, 81.7 years), male youth with PHIV and youth with NPHIV had projected life expectancy losses of 10.4 years (95% CI, 5.5-18.1)...
This adolescent-focused microsimulation modeling analysis projected that youth with HIV would have shorter life expectancy than youth without HIV. Projected differences were larger for youth with NPHI...
Schizophrenia is associated with a wide range of socioeconomic and health-related problems, as well as 10-25 potential life-years lost. While lifestyle choices, comorbidities, and choice of medication...
In this study, register-based, nationwide data from patients with schizophrenia in Finland during 1972-2015 were analysed to determine influential factors associated with mortality and to demonstrate ...
Factors reducing all-cause mortality were use of antipsychotics: HR 0.46 (95 % CI: 0.45, 0.47), ever use of lipid-modifying agents: HR 0.71 (95 % CI 0.68, 0.73), antidepressants HR 0.87 (95 % CI 0.85,...
The results from this study could serve to motivate clinicians to support and encourage patients to adhere to antipsychotic treatment and achieve a healthier lifestyle, which could, in turn, increase ...
The median survival time of newly-diagnosed MS patients without severe disabilities is approximately 30-35 years. The prognosis after the onset of severe disability has not been reported. Based on Har...